Re-operations for early postoperative complications after CRS and HIPEC: indication, timing, procedure, and outcome

Published on 2019in Langenbeck's Archives of Surgery2.09
· DOI :10.1007/s00423-019-01808-8
Sebastian Blaj , Sebastian D. Nedelcut1
Estimated H-index: 1
+ 4 AuthorsPompiliu Piso35
Estimated H-index: 35
Purpose Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have become standard of care for many peritoneal malignancies in selected patients. Nevertheless, this aggressive treatment strategy is associated with significant major morbidity. The aim of the present study is to analyze the re-operation rate and clinical outcome following CRS and HIPEC.
  • References (25)
  • Citations (0)
Published on Jun 20, 2018in Journal of Clinical Oncology28.25
F. Quenet23
Estimated H-index: 23
D. Elias80
Estimated H-index: 80
+ 14 AuthorsG. Lorimier18
Estimated H-index: 18
LBA3503Background: Promising results have been obtained during the last decade using cytoreductive surgery (CRS) plus HIPEC for selected patients with colorectal PC who are amenable to complete macroscopic resection. This is the first trial to evaluate the specific role of HIPEC, after CRS, for the treatment of PC of colorectal origin. Methods: Prodige 7 is a randomized phase III, multicenter trial. Patients with histologically proven and isolated PC, peritoneal cancer index (PCI) ≤25 were eligi...
Published on Aug 1, 2016in Journal of Surgical Oncology3.11
Ida S. Frøysnes1
Estimated H-index: 1
(University of Oslo),
Stein Gunnar Larsen14
Estimated H-index: 14
(Oslo University Hospital)
+ 2 AuthorsKjersti Flatmark26
Estimated H-index: 26
Background and Objectives Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can offer long-term survival to patients with resectable peritoneal metastasis (PM) from colorectal cancer (CRC), a condition with otherwise dismal prognosis. This study describes short- and long-term outcome in a national patient cohort and aims to identify prognostic factors. Methods All patients treated with CRS-HIPEC for non-appendiceal PM-CRC in Norway 2004–2013 were included (n = 119...
Published on Sep 1, 2015in Colorectal Disease3.00
Brendan J Moran Frcsi49
Estimated H-index: 49
T. Cecil14
Estimated H-index: 14
+ 3 AuthorsA. K. Venkatasubramaniam2
Estimated H-index: 2
Aim The study determined the outcome of 1200 consecutive patients treated for peritoneal malignancy in one surgical unit over a 20-year period. Method A retrospective analysis was conducted of a custom designed prospective database of patients undergoing surgery for peritoneal malignancy since 1994. Patient demographics, tumour type, extent of surgery and outcome were recorded. Results Between 1994 and January 2014 (when the 1200th case had undergone surgery) 2956 patients were referred with a d...
Published on May 1, 2015in Annals of Surgical Oncology3.68
Andrea N. Doud7
Estimated H-index: 7
(Wake Forest University),
Reese W. Randle10
Estimated H-index: 10
(Wake Forest University)
+ 5 AuthorsKonstantinos I. Votanopoulos19
Estimated H-index: 19
(Wake Forest University)
Background Left upper quadrant involvement by peritoneal surface disease (PSD) may require distal pancreatectomy (DP) to obtain complete cytoreduction. Herein, we study the impact of DP on outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
Published on May 1, 2015in Annals of Surgical Oncology3.68
Stephanie Downs-Canner8
Estimated H-index: 8
(University of Pittsburgh),
Ying Ding12
Estimated H-index: 12
(University of Pittsburgh)
+ 9 AuthorsHerbert J. Zeh60
Estimated H-index: 60
(University of Pittsburgh)
Background Postoperative pancreatic fistulas (POPFs) are potentially morbid complications that often require therapeutic interventions. Distal pancreatectomy performed during cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) puts patients at risk for POPF. The authors hypothesized that POPFs are more severe after CRS/HIPEC than after pancreatectomy alone.
Published on Dec 1, 2014in Annals of Surgical Oncology3.68
William Jimenez6
Estimated H-index: 6
(Mercy Medical Center (Baltimore, Maryland)),
Armando Sardi19
Estimated H-index: 19
(Mercy Medical Center (Baltimore, Maryland))
+ 5 AuthorsVadim Gushchin14
Estimated H-index: 14
(Mercy Medical Center (Baltimore, Maryland))
Background Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has survival benefit in the treatment of selected patients with peritoneal carcinomatosis (PC) from appendiceal cancer (AC). We evaluated factors affecting the survival of patients with PC from AC after CRS/HIPEC.
Published on Jun 1, 2014in Langenbeck's Archives of Surgery2.09
Ingmar Königsrainer19
Estimated H-index: 19
(University of Tübingen),
Philipp Horvath5
Estimated H-index: 5
(University of Tübingen)
+ 4 AuthorsStefan Beckert17
Estimated H-index: 17
(University of Tübingen)
Background This investigation aims to assess morbidity, mortality and postoperative outcomes of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer (REOC) with peritoneal metastases (PM).
Published on May 1, 2014in Journal of Gastrointestinal Surgery2.69
Parissa Tabrizian16
Estimated H-index: 16
(Mount Sinai Hospital),
Brian Shrager8
Estimated H-index: 8
(Morristown Medical Center)
+ 5 AuthorsDaniel Labow22
Estimated H-index: 22
(Mount Sinai Hospital)
Background Cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) is an effective but morbid procedure in the treatment of peritoneal carcinomatosis. We report our outcomes at a single tertiary institution.
Published on Feb 1, 2014in JAMA Surgery10.67
Mehraneh D. Jafari11
Estimated H-index: 11
(UCI: University of California, Irvine),
Wissam J. Halabi17
Estimated H-index: 17
(UCI: University of California, Irvine)
+ 4 AuthorsAlessio Pigazzi37
Estimated H-index: 37
(UCI: University of California, Irvine)
Importance Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery have been shown to benefit selected patients with peritoneal carcinomatosis. However, these procedures are associated with high morbidity and mortality. Available data investigating the outcomes of HIPEC are mostly limited to single-center studies. To date, there have been few large-scale studies investigating the postoperative outcomes of HIPEC. Objective To determine the associated 30-day morbidity and morta...
Published on Aug 1, 2012in Annals of Surgery9.48
Dario Baratti41
Estimated H-index: 41
Shigeki Kusamura35
Estimated H-index: 35
+ 3 AuthorsMarcello Deraco41
Estimated H-index: 41
Objective: To assess the influence of parietal and visceral peritonectomy procedures on moderate/severe morbidity in patients undergoing surgical cytoreducion and hyperthermic intraperitoneal chemotherapy (HIPEC) and to identify subgroups of patients at highest operative risk. Background: Cytoreducion with HIPEC is an effective but potentially morbid treatment option for peritoneal surface malignancies. Although complication rates have recently decreased with increasing experience, risk-factors ...
Cited By0